Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||
Goods sale service render cash | 23.49%139.57B | 16.67%98.6B | 9.74%57.92B | 9.23%26.86B | -11.29%113.02B | 1.67%84.51B | 13.66%52.78B | 29.17%24.59B | 58.95%127.4B | 45.38%83.13B |
Refunds of taxes and levies | ---- | ---- | ---- | ---- | -92.36%13.93M | -91.99%13.9M | -90.40%13.98M | -55.21%5.59M | 9,173.53%182.27M | --173.47M |
Cash received relating to other operating activities | 25.57%7.34B | 61.04%7.44B | 7.84%4.09B | 13.19%1.89B | 38.00%5.84B | 66.05%4.62B | 110.02%3.79B | 69.37%1.67B | -8.78%4.24B | -19.35%2.78B |
Cash inflows from operating activities | 23.58%146.91B | 18.95%106.04B | 9.59%62.01B | 9.45%28.74B | -9.82%118.88B | 3.56%89.15B | 16.94%56.58B | 31.09%26.26B | 55.46%131.82B | 41.99%86.08B |
Goods services cash paid | 2.56%86.81B | -11.20%58.95B | -26.24%34.24B | -35.40%15.61B | -6.75%84.65B | 6.14%66.38B | 23.79%46.42B | 73.85%24.17B | 93.72%90.78B | 90.53%62.54B |
Staff behalf paid | 8.52%18.22B | 4.39%13.24B | -1.56%8.45B | -1.38%4.32B | 13.21%16.79B | 16.03%12.68B | 17.64%8.58B | 17.34%4.38B | 3.70%14.83B | 5.48%10.93B |
All taxes paid | 18.80%227.95M | 18.15%168.59M | 6.88%113.58M | 9.80%56.22M | 7.29%191.88M | 18.81%142.7M | 37.21%106.27M | 32.07%51.2M | 74.00%178.85M | 86.98%120.11M |
Cash paid relating to other operating activities | -44.22%4.11B | 38.75%4.5B | 48.05%3.74B | 143.23%3.69B | 143.37%7.36B | 23.45%3.25B | -24.15%2.52B | -37.28%1.52B | -58.21%3.02B | -35.57%2.63B |
Cash outflows from operating activities | 0.35%109.37B | -6.78%76.86B | -19.25%46.53B | -21.38%23.68B | 0.16%108.99B | 8.18%82.46B | 19.57%57.62B | 49.89%30.11B | 58.85%108.81B | 61.03%76.22B |
Net cash flows from operating activities | 279.50%37.54B | 336.27%29.18B | 1,582.11%15.47B | 231.48%5.07B | -57.01%9.89B | -32.17%6.69B | -648.29%-1.04B | -6,520.16%-3.85B | 41.21%23.01B | -25.83%9.86B |
Investing cash flow | ||||||||||
Cash received from disposal of investments | 626.02%20.03B | 492.68%6.99B | 269.92%2.35B | 195.65%836.7M | 804.71%2.76B | 660.65%1.18B | --636M | --283M | --305M | --155M |
Cash received from returns on investments | 178.25%44.41M | 529.04%15.69M | 331.37%6.03M | 588.13%4.46M | 1,590.34%15.96M | 319.79%2.49M | --1.4M | --648.4K | -85.38%944.17K | -89.20%594.17K |
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 136.41%137.24M | 98.83%94.7M | 267.24%59.57M | -45.04%5.83M | 27.29%58.05M | 115.52%47.63M | 148.90%16.22M | 539.79%10.6M | 210.28%45.6M | 81.20%22.1M |
Cash inflows from investing activities | 613.47%20.22B | 477.49%7.1B | 269.99%2.42B | 187.85%846.99M | 705.97%2.83B | 591.71%1.23B | 9,929.42%653.62M | 17,659.82%294.25M | 1,561.56%351.55M | 734.80%177.69M |
Cash paid to acquire fixed assets intangible assets and other long-term assets | -27.24%12.38B | -26.56%10.17B | -37.20%6B | 18.57%4.81B | 8.11%17.02B | 19.19%13.84B | 19.86%9.55B | -31.38%4.06B | -56.10%15.74B | -58.85%11.61B |
Cash paid to acquire investments | 593.80%21.07B | 377.64%9.59B | 247.31%2.75B | 414.66%1.46B | 460.91%3.04B | 508.24%2.01B | 1,681.08%790.8M | --283M | 297.03%541.35M | 184.73%330.15M |
Cash paid relating to other investing activities | --13.59M | --9.96M | --7.21M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash outflows from investing activities | 66.87%33.46B | 24.71%19.77B | -15.39%8.75B | 44.39%6.27B | 23.17%20.05B | 32.71%15.85B | 29.06%10.35B | -26.59%4.34B | -54.76%16.28B | -57.87%11.94B |
Net cash flows from investing activities | 23.07%-13.25B | 13.35%-12.67B | 34.63%-6.34B | -33.96%-5.42B | -8.10%-17.22B | -24.27%-14.62B | -21.00%-9.69B | 31.55%-4.05B | 55.71%-15.93B | 58.46%-11.77B |
Financing cash flow | ||||||||||
Cash received from capital contributions | -4.54%1.02B | --0 | ---- | -99.28%7.26M | -89.01%1.07B | -63.94%1.05B | -46.22%1.03B | -47.06%1.01B | 437,449.88%9.72B | 130,780.14%2.91B |
-Including: Cash received from capital contributions by minority shareholders of subsidiaries | -0.97%1.02B | ---- | ---- | ---- | -41.81%1.03B | 1.50%1.02B | --1B | --1B | 79,547.21%1.77B | 44,898.43%1B |
Cash from borrowing | -4.90%68.14B | -1.33%53.8B | -3.41%42.2B | 6.94%28.08B | 7.62%71.65B | 10.17%54.53B | 7.76%43.68B | 2.17%26.26B | 35.10%66.58B | 38.92%49.49B |
Cash received relating to other financing activities | -97.08%2.47M | -98.44%1.3M | -95.99%1.3M | -98.77%1M | --84.62M | 1,145,397.22%83.62M | 25,077.95%32.42M | --81.1M | ---- | -99.94%7.3K |
Cash inflows from financing activities | -5.00%69.16B | -3.34%53.8B | -5.69%42.2B | 2.71%28.09B | -4.59%72.8B | 6.22%55.66B | 5.41%44.74B | -0.93%27.35B | 54.80%76.3B | 47.02%52.4B |
Borrowing repayment | 37.93%73.61B | 56.27%59.14B | 64.61%46.06B | 77.40%24.46B | -16.94%53.37B | -14.19%37.84B | -11.94%27.98B | -25.57%13.79B | 160.64%64.25B | 156.00%44.1B |
Dividend interest payment | 6.57%8.26B | -55.38%3.17B | 4.75%2.01B | 1.42%1.19B | 84.86%7.75B | 112.22%7.11B | -24.77%1.92B | 68.80%1.17B | -53.26%4.19B | -59.64%3.35B |
-Including:Cash payments for dividends or profit to minority shareholders | 0.01%1.19B | 0.01%1.19B | -0.36%710.34M | -12.40%525.99M | 231.93%1.18B | 472.45%1.18B | 614.65%712.89M | 501.91%600.43M | -76.22%357M | -85.77%207M |
Cash payments relating to other financing activities | 47.53%12.53B | -18.46%6.04B | -66.08%2.47B | -78.86%469.68M | 56.10%8.49B | 343.64%7.4B | 243.49%7.28B | 981.89%2.22B | 262.38%5.44B | 208.12%1.67B |
Cash outflows from financing activities | 35.61%94.39B | 30.54%68.34B | 35.93%50.54B | 52.02%26.11B | -5.79%69.6B | 6.59%52.35B | 2.02%37.18B | -11.55%17.18B | 110.37%73.88B | 88.43%49.12B |
Net cash flows from financing activities | -888.65%-25.23B | -539.81%-14.54B | -210.29%-8.34B | -80.55%1.98B | 32.16%3.2B | 0.63%3.31B | 25.99%7.56B | 24.25%10.17B | -82.92%2.42B | -65.69%3.29B |
Net cash flow | ||||||||||
Exchange rate change effecting cash and cash equivalents | 99.62%-25.86K | 99.62%-26.33K | 100.10%7.01K | 99.99%-547.7 | -1,191.10%-6.87M | -289,809.60%-6.87M | -8,262,422.48%-6.87M | -143,857,279.79%-6.91M | 79,712.42%629.42K | -388.24%-2.37K |
Net increase in cash and cash equivalents | 77.46%-931.84M | 142.49%1.97B | 125.06%796.59M | -28.34%1.62B | -143.50%-4.13B | -436.04%-4.63B | -75.07%-3.18B | 2.19%2.27B | 272.73%9.5B | 125.27%1.38B |
Add:Begin period cash and cash equivalents | -23.08%13.78B | -23.08%13.78B | -23.08%13.78B | -23.08%13.78B | 113.03%17.91B | 113.03%17.91B | 113.03%17.91B | 113.03%17.91B | -39.56%8.41B | -39.56%8.41B |
End period cash equivalent | -6.76%12.84B | 18.59%15.75B | -1.07%14.57B | -23.67%15.4B | -23.08%13.78B | 35.66%13.28B | 123.49%14.73B | 89.90%20.18B | 113.03%17.91B | 15.78%9.79B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | ZTE Accounting firm (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.